Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia in Patients Presenting in the Outpatient Department of Neurology, Jinnah Postgraduate Medical Centre
DOI:
https://doi.org/10.54112/bcsrj.v6i4.1617Keywords:
Oxcarbazepine, Carbamazepine, Trigeminal Neuralgia, EfficacyAbstract
Trigeminal neuralgia is a chronic pain condition characterized by recurrent episodes of severe facial pain. Carbamazepine is the first-line pharmacological treatment, but oxcarbazepine has emerged as a potential alternative with better tolerability and fewer side effects. Objective: To compare the efficacy of oxcarbazepine and carbamazepine in managing trigeminal neuralgia in patients presenting to the outpatient department of Neurology at Jinnah Postgraduate Medical Centre (JPMC), Karachi. Methods: This randomized controlled trial was conducted at Ward 28, Department of Neurology, JPMC, Karachi, from 21st September 2024 to 21st March 2025 after ethical approval from the institutional review board. A total of 122 patients aged 25–80 years of either gender with a clinical diagnosis of trigeminal neuralgia were enrolled using non-probability consecutive sampling. Patients with a history of surgical intervention for trigeminal neuralgia were excluded. Participants were randomly assigned to receive either oxcarbazepine or carbamazepine, and treatment efficacy was evaluated using the Visual Analogue Scale (VAS) for pain intensity. The primary endpoint was pain relief, and treatment response was categorized as good, moderate, or unresponsive. Results: Patients treated with oxcarbazepine demonstrated significantly greater pain relief than those on carbamazepine, as reflected by a lower mean VAS score (2.6 ± 1.2 vs. 3.7 ± 1.89, p = 0.001). Efficacy analysis revealed a good response in 69% of the oxcarbazepine group compared to only 20% in the carbamazepine group (p < 0.0001). Moreover, 66% of patients in the carbamazepine group remained unresponsive, whereas only 13% in the oxcarbazepine group showed no improvement. Conclusion: Oxcarbazepine is more effective and better tolerated than carbamazepine in managing trigeminal neuralgia, providing superior pain control and a more favorable response profile. These findings support oxcarbazepine as a preferable first-line treatment option in clinical practice.
Downloads
References
Mannerak MA, Lashkarivand A, Eide PK. Trigeminal neuralgia and genetics: A systematic review. Molecular pain. 2021; 17:17448069211016139.
Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal neuralgia: basic and clinical aspects. Current neuropharmacology. 2020; 18(2):109-19.
Zhao X, Ge S. The efficacy and safety of gabapentin vs. carbamazepine in patients with primary trigeminal neuralgia: A systematic review and meta-analysis. Frontiers in Neurology. 2023; 14:1045640.
Naderi Y, Rad M, Sadatmoosavi A, Khaleghi E, Khorrami Z, Chamani G, et al. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and Experimental Dental Research. 2024; 10(2):e882.
Guo M, Shen W, Zhou M, Song Y, Liu J, Xiong W, et al. Safety and efficacy of carbamazepine in treating trigeminal neuralgia: A meta-analysis in biomedicine. Mathematical Biosciences and Engineering. 2024; 21(4):5335-59.
Di Stefano G, De Stefano G, Leone C, Di Lionardo A, Di Pietro G, Sgro E, et al. Real-world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia. European journal of pain (London, England). 2021; 25(5):1064-71.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. The Lancet. 2021; 397(10282):1363-74.
Rana MH, Khan AAG, Khalid I, Ishfaq M, Javali MA, Baig FAH, et al. Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review. Biomedicines. 2023; 11(10).
Di Stefano G, Truini A, Cruccu G. Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia. Drugs. 2018; 78(14):1433-42.
Paiker S, Mehdi SMZ, Khattak F, Hassan L, Muzaffar A, Bashir K. Clinical Efficacy of Oxcarbazepine compared with Carbamazepine in terms of Pain Relief in the Management of Trigeminal Neuralgia: Oxcarbazepine vs Carbamazepine for Pain Relief in Trigeminal Neuralgia: A Comparative Analysis. Annals of Punjab Medical College. 2024; 18(1):36-41.
Ravula JD, Nirogi R, Janodia MD. Review on 505 (b) (2) drug products approved by the USFDA from 2010 to 2020, emphasizing intellectual property and regulatory considerations for reformulations and new combinations. Journal of Pharmaceutical Sciences. 2023; 112(8):2146-75.
Besi E, Boniface DR, Cregg R, Zakrzewska JM. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in treating trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). The Journal of Headache and Pain. 2015; 16(1):81.
Beydoun A, DuPont S, Zhou D, Matta M, Nagire V, Lagae L. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure. 2020; 83:251-63.
Afsar MN, Afroze S, Urmi SA, Qureshi A, Kader MA, Hossain S, et al. The Efficiency of Oxcarbazepine and Carbamazepine in the Management of Trigeminal Neuralgia: First Comparative Study in Bangladesh. Journal of Dentistry and Allied Science. 2024; 7(1):35-44.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rizwana Malahat Ahmad, Khalid Sher, Lata Devi, Ateeba Abrar, . Nisha, Fatima Ghulam Muhammad

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.